Ease of use of two autoinjectors in patients with multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: results of the randomized, crossover REDEFINE study

References

• Wray S, Armstrong R, Herrman C, et al. Results from the single-use autoinjector for self-administration of subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis (MOSAIC) study. Expert Opin Drug Deliv. 2011;8:1543–1553.
   PubMed Web of Science ®Google Scholar
• Lugaresi A, Durastanti V, Gasperini C, et al. Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study. Clin Neuropharmacol. 2008;31:167–172.
   PubMed Web of Science ®Google Scholar
• Devonshire V, Lapierre Y, MacDonell C, et al. The Global Adherence Project - a multicentre observational study on adherence to disease-modifying therapies in patients suffering from relapsing-remitting multiple sclerosis. Mult Scler. 2006;12(Suppl. 1):S229–S243.
   Google Scholar
• Simeoni M, Auquier P, Fernandez O, et al. Validation of the Multiple Sclerosis International Quality of Life questionnaire. Mult Scler. 2008;14:219–230.
   PubMed Web of Science ®Google Scholar
• Devonshire V, Arbizu T, Borre B, et al. Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb study. BMC Neurol. 2010;10:28.
   PubMed Web of Science ®Google Scholar
• Singer B, Wray S, Miller T, et al. Patient-rated ease of use and functional reliability of an electronic autoinjector for self-injection of subcutaneous interferon beta-1a for relapsing multiple sclerosis. Mult Scler Related Disord. 2012;1:87–94.
   PubMed Web of Science ®Google Scholar
• Bayas A, Ouallet JC, Kallmann B, et al. Adherence to, and effectiveness of, subcutaneous interferon beta-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational SMART study. Expert Opin Drug Deliv. 2015;12:1239–1250.
   PubMed Web of Science ®Google Scholar
• Boeru G, Milanov I, De RF, et al. ExtaviJect® 30G device for subcutaneous self-injection of interferon beta-1b for multiple sclerosis: a prospective European study. Med Devices (Auckl). 2013;6:175–184.
   PubMedGoogle Scholar
• Hupperts R, Becker V, Friedrich J, et al. Multiple sclerosis patients treated with intramuscular IFN-beta-1a autoinjector in a real-world setting: prospective evaluation of treatment persistence, adherence, quality of life and satisfaction. Expert Opin Drug Deliv. 2015;12:15–25.
   PubMed Web of Science ®Google Scholar
• Lugaresi A, De RF, Clerico M, et al. Long-term adherence of patients with relapsing-remitting multiple sclerosis to subcutaneous self-injections of interferon beta-1a using an electronic device: the RIVER study. Expert Opin Drug Deliv. 2016;13:931–935.
   PubMed Web of Science ®Google Scholar
• Masid ML, Ocana RH, Gil MJ, et al. A patient care program for adjusting the autoinjector needle depth according to subcutaneous tissue thickness in patients with multiple sclerosis receiving subcutaneous injections of glatiramer acetate. J Neurosci Nurs. 2015;47:E22–E30.
   PubMed Web of Science ®Google Scholar
• Pozzilli C, Schweikert B, Ecari U, et al. Quality of life and depression in multiple sclerosis patients: longitudinal results of the BetaPlus study. J Neurol. 2012;259:2319–2328.
   PubMedGoogle Scholar
• Willis H, Webster J, Larkin AM, et al. An observational, retrospective, UK and Ireland audit of patient adherence to subcutaneous interferon beta-1a injections using the RebiSmart((R)) injection device. Patient Prefer Adherence. 2014;8:843–851.
   PubMed Web of Science ®Google Scholar
• D’Arcy C, Thomas D, Stoneman D, et al. Patient assessment of an electronic device for subcutaneous self-injection of interferon beta-1a for multiple sclerosis: an observational study in the UK and Ireland. Patient Pref Adherence. 2012;6:55–61.
   PubMed Web of Science ®Google Scholar
• Weller I, Saake A, Schreiner T, et al. Patient satisfaction with the BETACONNECT autoinjector for interferon beta-1b. Patient Prefer Adherence. 2015;9:951–959.
   PubMed Web of Science ®Google Scholar
• Ziemssen T, Sylvester L, Rametta M, et al. Patient Satisfaction with the New Interferon Beta-1b Autoinjector (BETACONNECT). Neurol Ther. 2015;4:125–136.
   PubMed Web of Science ®Google Scholar
• Mikol D, Lopez-Bresnahan M, Taraskiewicz S, et al. A randomized, multicentre, open-label, parallel-group trial of the tolerability of interferon beta-1a (Rebif®) administered by autoinjection or manual injection in relapsing-remitting multiple sclerosis. Mult Scler. 2005;11:585–591.
   PubMed Web of Science ®Google Scholar
• Phillips JT, Fox E, Grainger W, et al. An open-label, multicenter study to evaluate the safe and effective use of the single-use autoinjector with an Avonex® prefilled syringe in multiple sclerosis subjects. BMC Neurol. 2011;11:126.
   PubMed Web of Science ®Google Scholar
• Seddighzadeh A, Hung S, Selmaj K, et al. Single-use autoinjector for peginterferon-beta1a treatment of relapsing-remitting multiple sclerosis: safety, tolerability and patient evaluation data from the Phase IIIb ATTAIN study. Expert Opin Drug Deliv. 2014;11:1713–1720.
   PubMed Web of Science ®Google Scholar
• Brochet B, Lemaire G, Beddiaf A. [Reduction of injection site reactions in multiple sclerosis (MS) patients newly started on interferon beta 1b therapy with two different devices]. Rev Neurol (Paris). 2006;162:735–740. French.
   PubMed Web of Science ®Google Scholar
• Cramer JA, Cuffel BJ, Divan V, et al. Patient satisfaction with an injection device for multiple sclerosis treatment. Acta Neurol Scand. 2006;113:156–162.
   PubMed Web of Science ®Google Scholar
• de Sá J, Urbano G, Reis L. Assessment of new application system in Portuguese patients with relapsing-remitting multiple sclerosis. Curr Med Res Opin. 2010;26:2237–2242.
   PubMed Web of Science ®Google Scholar